Rubinger M, Plenderleith I H, Lertzman M, Worth A J
Department of Internal Medicine, University of Manitoba, Winnipeg, Canada.
Chest. 1995 Jul;108(1):281-2. doi: 10.1378/chest.108.1.281.
A patient with pulmonary metastatic extraskeletal myxoid chondrosarcoma (EMC), of unknown cause, responded dramatically to 16 months of therapy with interferon alfa-2b. This is the first report of a significant response of a patient with EMC to this novel treatment approach.
一名病因不明的肺转移性骨外黏液样软骨肉瘤（EMC）患者，对干扰素α-2b进行的16个月治疗产生了显著反应。这是首例关于EMC患者对这种新治疗方法产生显著反应的报告。
